{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Karyopharm Therapeutics Inc."},"Symbol":{"label":"Symbol","value":"KPTI"},"Address":{"label":"Address","value":"85 WELLS AVENUE,2ND FLOOR, NEWTON, Massachusetts, 02459, United States"},"Phone":{"label":"Phone","value":"+1 617 658-0600"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharm's lead compound, XPOVIO(R) (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade(R) (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma."},"CompanyUrl":{"label":"Company Url","value":"https://www.karyopharm.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Amama Sadiq","title":"Senior VP-Global Medical & Scientific Affairs"},{"name":"Reshma Rangwala","title":"Chief Medical Officer & Executive Vice President"},{"name":"Richard A. Paulson","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}